SNGX

buy

Soligenix Inc

Analyst ↑

$1.20

-1.64%

Vol: 0 (NaNx avg)

Market Cap

$12M

52W High

$6.23

52W Low

$1.02

P/E Ratio

—

EPS (TTM)

—

Beta

2.03

Sector

Biotechnology

Price Target

—

Why SNGX Is in Focus Today

SNGX is down 1.6% today. Price action and volume signal this is worth watching.

Bull Case

Recent catalysts: Soligenix Says Summary Of All Clinical Trials Completed To Date Of Hybryte (Synthetic Hypericin) For Cutaneous T-Cell Lymphoma Has Been Published In The Peer-reviewed Medical Journal Expert Opinion On Investigational Drugs

Bear Case

Watch for reversal signals. High volatility names carry elevated risk. Always size positions according to your risk tolerance.

Recent News

Soligenix Says Summary Of All Clinical Trials Completed To Date Of Hybryte (Synthetic Hypericin) For Cutaneous T-Cell Lymphoma Has Been Published In The Peer-reviewed Medical Journal Expert Opinion On Investigational Drugs

Benzinga · Mar 19, 2026

Volume Analysis

Today0

30D Avg0

MultipleNaNx avg

Analysis is for informational purposes only. Not financial advice. Always conduct your own due diligence before making investment decisions.